Business Insider

Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate

TARRYTOWN, N.Y. and PARIS, March 10, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing ...
News Medical

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the ...
WTEN

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...
TCTMD

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

TARRYTOWN, Regeneron Pharmaceuticals, Inc. Sanofi today announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the ...
Nasdaq

FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization

Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause Praluent treatment effect was observed in patients already receiving other lipid-lowering therapies, ...
FiercePharma

Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

- Praluent will be available in both a 75 mg and 150 mg dose for self-administration every two weeks - Paris and Tarrytown, New York - September 28, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc.
FiercePharma

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

TARRYTOWN, N.Y. and PARIS, July 8, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy ...
The Telegraph

Praluent injections significantly decrease LDL level

DEAR DR. ROACH: I am a 66-year-old male diagnosed about 15 years ago with mild coronary artery disease, with some blockages in my peripheral arteries. I was taking the maximum recommended dosage of ...
Business Insider

Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate

PARIS and TARRYTOWN, N.Y., March 10, 2018 /PRNewswire/ -- Sanofi (EURONEXT: SAN) (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. today announced that the ODYSSEY OUTCOMES trial met its primary ...
TCTMD

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Praluent will be available in both a 75 mg and 150 mg dose for self-administration every two weeks TARRYTOWN, N.Y. and PARIS, Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the ...
Sun Journal

Praluent injections significantly decrease LDL level

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am a 66-year-old male diagnosed about 15 years ago with ...